|Application ||FC, IHC-P, WB, IF, E|
|Calculated MW||15887 Da|
|Antigen Region||71-98 aa|
|Other Names||Transthyretin, ATTR, Prealbumin, TBPA, TTR, PALB|
|Target/Specificity||This TTR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 71-98 amino acids from the C-terminal region of human TTR.|
|Precautions||TTR Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.|
|Cellular Location||Secreted. Cytoplasm.|
|Tissue Location||Detected in serum and cerebrospinal fluid (at protein level). Highly expressed in choroid plexus epithelial cells. Detected in retina pigment epithelium and liver|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transthyretin, one of the three prealbumins including alpha-1-antitrypsin, transthyretin and orosomucoid. Transthyretin is a carrier protein; it transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma. The protein consists of a tetramer of identical subunits. More than 80 different mutations in this gene have been reported; most mutations are related to amyloid deposition, affecting predominantly peripheral nerve and/or the heart, and a small portion of the gene mutations is non-amyloidogenic. The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis, carpal tunnel syndrome, etc.
Lee,K.W., Biochem. Biophys. Res. Commun. 388 (2), 256-260 (2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.